10-Q: Neumora Reports Q3 Losses, Navacaprant Phase 3 Fails

Neumora Therapeutics reported continued net losses in Q3 2025, a significant reduction in cash, and a major setback with its lead candidate navacaprant failing its Phase 3 primary endpoint.

Summary

• Neumora Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $56.8 million for the three months ended September 30, 2025, and $177.5 million for the nine months ended September 30, 2025.
• The company's accumulated deficit reached $1,124.7 million as of September 30, 2025.
• Cash, cash equivalents, and marketable securities decreased to $171.5 million as of September 30, 2025, down from $290.7 million at December 31, 2024.
• Research and development (R&D) expenses decreased by 33% to $40.5 million for the three months ended September 30, 2025, and by 15% to $131.4 million for the nine months ended September 30, 2025.
• General and administrative (G&A) expenses decreased by 24% to $12.2 million for the three months ended September 30, 2025, but slightly increased by 2% to $46.3 million for the nine months ended September 30, 2025.
• A $5.0 million acquired in-process research and development expense was recognized in Q3 2025 due to a Phase 1 development milestone under the Vanderbilt License Agreement.
• The KOASTAL-1 study for navacaprant (NMRA-140), a Phase 3 program for Major Depressive Disorder (MDD), did not demonstrate a statistically significant improvement on its primary or key secondary endpoints, as announced in January 2025.
• The company secured an additional $40.0 million in term loans from K2 HealthVentures LLC on November 4, 2025, following an initial $20.0 million in May 2025, bringing the total drawn to $60.0 million out of a potential $125.0 million facility.
• Neumora is advancing NMRA-511 (Phase 1b for agitation in Alzheimer's disease), NMRA-861 and NMRA-898 (Phase 1 SAD/MAD for M4 PAMs), and NMRA-215 (preclinical for obesity, Phase 1 initiation expected Q1 2026).
• The development of NMRA-266, another M4 PAM, has been discontinued.
• A securities class action lawsuit was filed on February 6, 2025, alleging violations of the Securities Act related to the company's September 2023 IPO, claiming false and misleading statements regarding navacaprant's prospects.

Sentiment

Score: 3

Explanation: The failure of the lead Phase 3 candidate, navacaprant, is a major negative event for a clinical-stage biopharmaceutical company. While some cost reductions were achieved, the substantial decline in cash and the explicit need for future capital raises indicate significant financial challenges and increased risk. The ongoing legal proceedings further add to the negative sentiment.

Positives

• Net loss decreased for both the three-month period ($56.8 million vs. $72.5 million in prior year) and the nine-month period ($177.5 million vs. $185.0 million in prior year).
• Research and development expenses decreased by $20.1 million (33%) for the three months and $23.6 million (15%) for the nine months ended September 30, 2025, primarily due to reduced navacaprant program costs and termination of the Amgen Collaboration Agreement.
• General and administrative expenses decreased by $3.8 million (24%) for the three months ended September 30, 2025.
• The company successfully drew an additional $40.0 million from its term loan facility with K2 HealthVentures LLC in November 2025, enhancing liquidity.
• Advancement of other pipeline candidates, including NMRA-511 in Phase 1b, NMRA-861 and NMRA-898 in Phase 1, and plans to initiate Phase 1 for NMRA-215 in Q1 2026.

Negatives

• The lead product candidate, navacaprant (NMRA-140), failed to meet its primary and key secondary endpoints in the KOASTAL-1 Phase 3 study, a significant clinical setback.
• Cash, cash equivalents, and marketable securities declined significantly from $290.7 million at December 31, 2024, to $171.5 million at September 30, 2025.
• The company continues to incur substantial net losses, with an accumulated deficit exceeding $1.1 billion.
• Net cash used in operating activities increased to $158.5 million for the nine months ended September 30, 2025, compared to $132.6 million in the prior year period.
• Interest income decreased by $2.5 million for the three months and $8.8 million for the nine months ended September 30, 2025, due to lower cash and marketable securities balances.
• The company discontinued the development of NMRA-266, an M4 PAM program.
• A securities class action lawsuit has been filed, alleging false and misleading statements related to the IPO and navacaprant's prospects.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history, no products approved for commercial sale, and expects to incur losses for the foreseeable future.
• Additional funding will be required to finance operations, and the inability to raise capital on acceptable terms could force delays or elimination of product development programs or commercialization efforts.
• Drug development for brain diseases has historically seen very limited success, making the ability to successfully develop drugs in these fields extremely difficult and subject to unique challenges.
• Investments in acquiring product candidates, technologies, and assets, as well as R&D efforts, may not yield expected returns or may develop more slowly than anticipated.
• Rapid growth since inception in November 2019 poses challenges in effectively managing growth, including scaling headcount, operations, and systems.
• The company operates in highly competitive and rapidly changing industries, facing competition from larger biopharmaceutical companies, academic institutions, and other research organizations.
• Clinical and preclinical drug development is a lengthy, expensive, and uncertain process, with programs experiencing delays or potentially never advancing.
• Product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that could delay or prevent marketing approval, or limit commercialization if identified post-approval.
• Interim, topline, or preliminary data from clinical trials may change as more patient data becomes available or manufacturing processes are altered, potentially leading to material changes in final data.
• Dependence on enrollment and retention of patients in clinical trials; delays or difficulties could materially adversely affect R&D efforts.
• Estimates of market opportunity and forecasts of market growth may prove to be smaller than believed, and products may not gain market acceptance even if approved.
• The company currently has no marketing, sales, or distribution infrastructure and faces substantial risks in establishing or outsourcing this function.
• Exposure to costly and damaging product liability claims, with insurance potentially not covering all damages.
• The development and commercialization of drug products are subject to extensive, lengthy, time-consuming, and inherently unpredictable regulatory approval processes.
• Ongoing obligations and continued regulatory review post-approval may result in significant additional expense and potential market withdrawal.
• Risks associated with off-label promotion and potential liability for improper promotion.
• Disruptions at the FDA and other government agencies due to funding shortages, staffing reductions, or global health concerns could hinder timely development, approval, or commercialization.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws and regulations.
• Research and development activities could be affected or delayed by restrictions on animal testing.
• Business operations and relationships with healthcare professionals are subject to applicable anti-kickback, fraud and abuse, false claims, and physician payment transparency laws and regulations.
• Reliance on third-party providers of cloud-based infrastructure; any disruption could adversely affect business.
• Security breaches or unauthorized access to data could lead to significant liabilities and reputational harm.
• Use of third-party open-source software entails risks of non-compliance with licenses, litigation, or intellectual property claims.
• Dependence on intellectual property licensed or acquired from third parties; breach or termination of agreements could result in loss of rights.
• Inability to successfully obtain or maintain necessary intellectual property rights for the product pipeline.
• Inability to protect intellectual property rights throughout the world, especially in countries with weaker IP laws or due to geopolitical actions.
• The lives of patents may not be sufficient to effectively protect products and business, leading to competition from biosimilar or generic medications.
• Claims challenging the inventorship or ownership of patents and other intellectual property.
• Inadequate protection of trademarks and trade names could hinder brand recognition.
• Stock price volatility and potential declines, regardless of operating performance.
• Inability to maintain Nasdaq listing could negatively affect trading price and volume.
• Quarterly operating results may fluctuate significantly or fall below expectations.
• Principal stockholders and management own a significant percentage of stock, exerting control over stockholder approval matters.
• Sales of a substantial number of shares by existing stockholders could cause the stock price to fall.
• No current intention to pay dividends; return on investment depends on stock price appreciation.
• Provisions in organizational documents and Delaware law might discourage, delay, or prevent a change in control or management.
• Exclusive forum provision for certain disputes could limit stockholders' ability to obtain a favorable judicial forum.
• Ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes.
• Unstable market and economic conditions may have serious adverse consequences on business and stock price.
• Lack of an active trading market for common stock may impair value and liquidity.
• Increased reporting and disclosure requirements as no longer an emerging growth company.
• Requirements of being a public company may strain resources, result in more litigation, and divert management's attention.
• Business disruptions (e.g., natural disasters, epidemics, cyberattacks) could seriously harm future revenue and financial condition.
• Failure to maintain proper and effective internal controls over financial reporting could impair ability to produce accurate and timely financial statements.
• Incorrect estimates or judgments relating to critical accounting policies or changes in financial reporting standards could adversely affect results of operations.
• Information technology systems, or those of third parties, may fail or suffer cyberattacks or security breaches.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Subject to current and potential future securities class action litigation.

Future Outlook

The company expects to incur additional losses in the future as it continues its research and development efforts, advances product candidates through preclinical and clinical development, expands its pipeline, seeks regulatory approval, and prepares for potential commercialization. It anticipates needing to raise additional capital to support continuing operations and long-term business plans, expecting to finance cash needs through public or private equity offerings, debt financings, or strategic collaborations. A Phase 1 study for NMRA-215 is expected to initiate in Q1 2026, with human proof of concept data anticipated in 2026.

Management Comments

• "We believe that our existing cash, cash equivalents and marketable securities as of September 30, 2025 will be sufficient to support operations for at least the next 12 months from the date these condensed consolidated financial statements are issued."
• "We expect to incur additional losses in the future as it continues its research and development efforts, advances its product candidates through preclinical and clinical development, expands its product pipeline, potentially seeks regulatory approval, prepares for potential commercialization, as well as hires additional personnel, protects its intellectual property and potentially grows its business."
• "The Company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete the development and commercialization of its product candidates, if approved."
• "We expect to finance our cash needs through a combination of public or private equity offerings or debt financings or other capital sources, which may include strategic collaborations or other arrangements with third parties, or other sources of financing."

Industry Context

The biopharmaceutical industry, particularly in brain disease drug development, is highly competitive, speculative, and has historically seen limited success despite significant R&D investment. The company highlights its 'precision neuroscience approach' as a differentiator, aiming to improve success rates by leveraging patient selection biomarkers, which have shown higher clinical development success rates (16% vs. 8% without biomarkers) according to the Biotechnology Innovation Organization. The industry also faces increasing regulatory scrutiny on drug pricing, evolving data protection laws (e.g., GDPR, EU AI Act, CCPA), and potential impacts from geopolitical actions and supply chain disruptions.

Comparison to Industry Standards

• The company positions its 'precision neuroscience approach' as a fundamentally different strategy to address the historical challenges and limited success in brain disease drug development, aiming to improve treatment outcomes and quality of life for patients.
• It references industry data from the Biotechnology Innovation Organization, noting that clinical development success rates for new drug candidates employing patient selection biomarkers (approximately 16%) are significantly higher than those without (approximately 8%), implying its approach aligns with a more successful industry trend.
• The company acknowledges the substantial R&D spending in neuroscience (over $110 billion since 2019 in the U.S.) but notes the low approval rate (approximately 12% of new therapies for brain diseases), indicating a challenging industry landscape that its strategy aims to overcome.
• No specific comparable companies, projects, or direct competitive results are detailed for a direct quantitative comparison within the filing.

Management Changes

Corporate Governance

Legal Proceedings

• On February 6, 2025, a purported stockholder filed a putative class action lawsuit against the company, certain executive officers, and underwriters in the U.S. District Court for the Southern District of New York (Case No. 1:25-cv-01072). The complaint alleges violations of the Securities Act of 1933 related to the company's initial public offering on September 15, 2023, claiming offering documents contained false and misleading statements and omitted material facts about navacaprant's prospects. The company intends to move to dismiss these allegations, believing they lack merit.

Related Party Transactions

• In May 2025, the company made a final payment of $6.3 million to Amgen under the Amgen Collaboration Agreement for research and development activities. The agreement automatically terminated in September 2024.
• The company has ongoing contingent consideration obligations to former stockholders of BlackThorn Therapeutics, Inc. and Vanderbilt University related to acquisitions and license agreements, which may be settled in cash or equity upon achievement of milestones.

Stakeholder Impact

• **Shareholders**: Significant dilution risk from future capital raises (equity or convertible debt) and the potential exercise of K2HV's conversion option. The failure of the lead Phase 3 candidate and the ongoing securities class action lawsuit are likely to negatively impact share price and investor confidence.
• **Employees**: Stock option repricing may improve morale for those with underwater options but also indicates past stock price underperformance. Lower personnel-related costs suggest potential headcount reductions or slower hiring, impacting employment stability.
• **Creditors (K2 HealthVentures LLC)**: The term loan amendment and additional funding provide continued financial support, but the modified liquidity covenants tie future requirements to operational milestones and market capitalization, linking their security to company performance.
• **Patients**: The failure of navacaprant's Phase 3 study means a potential treatment for MDD will not advance, impacting patients awaiting new therapies. Continued development of other pipeline candidates offers future hope but is subject to significant clinical risk.
• **Management**: Faces increased pressure to manage cash burn, secure additional financing, navigate legal proceedings, and deliver positive clinical results from earlier-stage pipeline assets.

Next Steps

• Continue advancing NMRA-511 through its Phase 1b signal-seeking study for agitation associated with dementia due to Alzheimer's disease.
• Continue advancing NMRA-861 and NMRA-898 through Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) studies.
• Initiate a Phase 1 study with NMRA-215 for the treatment of obesity in the first quarter of 2026.
• Report human proof of concept data for NMRA-215 in 2026.
• Manage and defend against the securities class action lawsuit filed on February 6, 2025.
• Monitor and maintain compliance with Nasdaq listing requirements, including the minimum bid price.
• Seek additional financing through public or private equity offerings, debt financings, or strategic collaborations to fund future operations and long-term business plans.

Key Dates

Recommendation

The failure of navacaprant, the company's lead Phase 3 candidate for MDD, to meet its primary and key secondary endpoints is a critical setback that significantly impacts the company's near-term commercial prospects and valuation. This clinical failure, combined with substantial ongoing net losses, a declining cash position, and the explicit need for further capital raises (which will likely be dilutive), creates a highly unfavorable investment outlook. While the company has other early-stage pipeline candidates, their success is uncertain and years away. The current financial and clinical challenges outweigh any cost-saving measures or early-stage pipeline advancements, making the stock a high-risk proposition with significant downside potential.

Keywords

Biopharmaceutical, Neuroscience, Major Depressive Disorder, Alzheimer's Disease, Obesity, Clinical-stage, Drug Development, SEC Filing, 10-Q, Navacaprant, NMRA-140, NMRA-511, NMRA-861, NMRA-898, NMRA-215, Kappa Opioid Receptor Antagonist, Vasopressin 1a Receptor Antagonist, M4 Positive Allosteric Modulator, NLRP3 Inhibitor, Clinical Trials, R&D Expenses, Net Loss, Liquidity, Capital Raise, Stock Option Repricing, Securities Litigation, K2 HealthVentures, Precision Neuroscience